Results 31 to 40 of about 3,046 (215)

Safety and efficacy of mavacamten for treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized clinical trials

The Egyptian Heart Journal, 2023
Background Mavacamten, an allosteric myosin inhibitor, is considered to be a promising drug for the treatment of hypertrophic cardiomyopathy (HCM). This meta-analysis aimed to explore the safety and efficacy of mavacamten in HCM patients.
Mehrdad Rabiee Rad, Ghazal Ghasempour Dabaghi, Danial Habibi   +2 more
doaj   +2 more sources

Echocardiographic Changes With Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy: Exploratory Insights From the ODYSSEY-HCM Trial.

Journal of the American College of Cardiology
BACKGROUND Symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM) lacks approved therapies. The ODYSSEY-HCM trial (A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy; NCT05582395), the largest to date in HCM patients, evaluating ...
Ananthasubramaniam Karthikeyan, Douglas Stoller   +1 more
exaly   +2 more sources

Serial Changes in Ventricular Strain in Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Insights From the VALOR-HCM Trial

Circulation: Cardiovascular Imaging
BACKGROUND: In severely symptomatic patients with obstructive hypertrophic cardiomyopathy, VALOR-HCM (A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy ...
Zoran B Popovic, Neal K Lakdawala, Albree Tower-Rader   +2 more
exaly   +2 more sources

Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Design, Rationale, and Baseline Characteristics of ODYSSEY-HCM.

JACC: Heart Failure
There are no approved therapies for patients with symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM). The authors describe the baseline characteristics of ODYSSEY-HCM (A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy), a ...
Milind Y. Desai, Steve E. Nissen, Theodore P. Abraham, I. Olivotto, P. García-Pavía, Renato D. Lopes, N. Verheyen, Omar Wever-Pinzon, K. Wolski, Wael A. Jaber, Lisa Mitchell, Deborah A. Davey, J. Myers, Thomas Rano, Vandana Bhatia, Y. Zhong, Suzanne Carter-Bonanza, V. Florea, Ron Aronson, A. Owens   +19 more
semanticscholar   +2 more sources

Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy [PDF]

European Heart Journal, 2023
Graphical Abstract Graphical Abstract The path to treatment of obstructive hypertrophic cardiomyopathy. (Top left) Haemodynamic observations demonstrated. Left ventricular (LV) obstruction and symptoms related to LV hypertrophy.
E. Braunwald, S. Saberi, T. Abraham, Perry M. Elliott, I. Olivotto   +4 more
semanticscholar   +5 more sources

Mavacamten facilitates myosin head ON‐to‐OFF transitions and shortens thin filament length in relaxed mouse skeletal muscle

Physiological Reports
The first‐in‐its‐class cardiac drug mavacamten shifts myosin heads towards a structurally inactive position where they lay along the helical tracks of the thick filament.
Michel N. Kuehn, Nichlas M. Engels, Devin L. Nissen, Johanna K. Freundt, Weikang Ma, Samantha P. Harris, Thomas C. Irving, Wolfgang A. Linke, Anthony L. Hessel   +8 more
doaj   +2 more sources

Tale of three services: early UK experience with mavacamten treatment for hypertrophic cardiomyopathy with left ventricular outflow tract obstruction

Open Heart
Background Hypertrophic cardiomyopathy (HCM) is characterised by abnormal thickening of ventricular myocardium. Left ventricular outflow tract (LVOT) obstruction occurs in up to 70% of patients, causing progressive symptoms, heart failure and mortality ...
Jane Draper, Antonio De Marvao, Robert M Cooper, Gerry Carr-White, Nabeel Sheikh, Rachel Bastiaenen, Yande Kasolo, Jason N Dungu, Edward Burford   +8 more
doaj   +2 more sources

Early Insights on Mavacamten Usage in Canada: A Retrospective Cohort Study of the Mavacamten Patient Support Program

CJC Open
Background: Only a limited amount of real-world data are available on the demographic and clinical characteristics of adult patients with obstructive hypertrophic cardiomyopathy (oHCM) treated with mavacamten in Canada.
Kevin Ong, MD, Patrick Garceau, MD, Andrew M. Crean, MD, Andrew D. Moeller, MD, Lou Kolman, MD, Stephanie Corriveau, PhD, Florence Brellier, PhD, Christina Wong, MHSc, Michael R. Ward, MD, PhD   +8 more
doaj   +3 more sources

Mavacamten Monotherapy in Real-World Patients With Obstructive Hypertrophic Cardiomyopathy: Evidence From COLLIGO-HCM

Circulation Genomic and Precision Medicine
BACKGROUND: Mavacamten has been shown to improve cardiac function and symptoms in patients with symptomatic (New York Heart Association class II–III) obstructive hypertrophic cardiomyopathy (HCM).
Garima Arora, Arnon Adler, Dajun Tian
exaly   +2 more sources

Alcohol Septal Ablation or Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Journal of Clinical Medicine, 2023
Hypertrophic cardiomyopathy (HCM) is a genetic disease characterized by an increased left ventricular wall thickness in the absence of increased afterload conditions. In addition to diastolic dysfunction, obstruction of the left ventricular outflow tract is common in HCM and has an important influence on symptoms and outcome. Over the last five decades
Scholtz, Smita (PD Dr. med.), Rudolph, Volker (PD Dr. med.), Reil, Jan-Christian (Dr. med.)   +2 more
core   +6 more sources